Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
BENEFITS Triple receptor activation studied for simultaneous GLP-1, GIP, and glucagon engagement Metabolic research explored in Phase 2 clinical trials with notable body-composition results Glucagon component linked to thermogenesis and energy-expenditure pathways Next-generation compound investigated as an advancement over dual-agonist approaches Comparative pharmacology assessed alongside mono- and dual-agonists in research settings WHAT RESEARCHERS LOOK AT Triple-agonist binding affinity across GLP-1, GIP, and glucagon receptors Additive effects of glucagon-receptor activation on energy expenditure Dose-response and tolerability profiling from clinical-trial data Comparative outcomes vs tirzepatide and semaglutide Pharmacokinetic profiling and receptor selectivity QUICK SPECS Form: Lyophilized peptide powder Net per vial: 10 mg Purity: 99% (HPLC verified) Identity: MS-verified (per COA) Storage: 28C, protect from light and moisture Reconstitution: Use bacteriostatic water (sold separately) IDENTITY BASICS CAS: 2381089-83-2 Classification: Triple GLP-1/GIP/glucagon receptor agonist WHY CHOOSE DURHAM PEPTIDES FOR RETATRUTIDE
Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A et al
The Precision Peptide Genetic Test (add-on at $99 after your first treatment month) maps your individual GLP-1 receptor sensitivity, helping provide pathway-level context (it does not predict your response) and optimize your treatment protocol before side effects significantly impact you
How should clinicians counsel patients about expectations
US$ 28.67
US$ 22.18
US$ 22.16
US$ 23.03
US$ 20.68
